{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:56:28Z","timestamp":1780584988929,"version":"3.54.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The risk of cardiovascular events remains after kidney transplantation (KT). Abnormal glucose metabolism and hyperlipidemia contribute partly to this risk. Among angiotensin II type-1 receptor blockers, telmisartan alone has been shown to ameliorate these effects on glucose and lipid metabolism (GLM). We investigated the effects of telmisartan on GLM in KT patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This trial had a crossover design. Forty-six KT patients with well-controlled hypertension under angiotensin II type-1 receptor blockers were randomized into telmisartan and candesartan groups. After a 12-week treatment, crossover was initiated, and additional 12-week treatment was administered without a washout period. We examined the laboratory parameters of GLM, blood pressure and graft function before and after each treatment period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty patients completed the scheduled treatment regimen. Serum levels of triglyceride were significantly lower (114.3 \u00b1 50.8 mg\/dL vs 136.5 \u00b1 66.8 mg\/dL; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.019), and the estimated glomerular filtration rate was significantly higher (50.4 \u00b1 15.1 mL\/min per 1.73 m<jats:sup>2<\/jats:sup> vs 48.5 \u00b1 12.5 mL\/min per 1.73 m<jats:sup>2<\/jats:sup>; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.038) after telmisartan treatment than after candesartan treatment. There were no significant differences between the 2 treatment groups with regard to the other parameters studied (including serum adiponectin levels and parameters of glucose metabolism).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These data suggest that telmisartan can improve serum triglyceride levels and graft function for KT patients better than candesartan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000861","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T02:36:23Z","timestamp":1548815783000},"page":"e423","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study"],"prefix":"10.1097","volume":"5","author":[{"given":"Yoshifumi","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Fukuoka University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Medical Information Center, Kyushu University Hospital, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,2]]},"reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2008.06.005","article-title":"A systematic review of kidney transplantation from expanded criteria donors","volume":"52","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00007890-198803000-00010","article-title":"Late mortality and morbidity five to eighteen years after kidney transplantation","volume":"45","year":"1988","journal-title":"Transplantation"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1046\/j.1523-1755.2002.00121.x","article-title":"Ischemic heart disease after renal transplantation","volume":"61","year":"2002","journal-title":"Kidney Int"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","article-title":"Incidence and long-term cost of steroid-related side effects after renal transplantation","volume":"33","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study group","volume":"63","year":"1997","journal-title":"Transplantation"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","year":"2006","journal-title":"Transplantation"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1432-2277.2006.00335.x","article-title":"Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients","volume":"19","year":"2006","journal-title":"Transpl Int"},{"issue":"6 Suppl","key":"bib8-20231002","first-page":"S5","article-title":"Epidemiology of cardiovascular disease after renal transplantation","volume":"72","year":"2001","journal-title":"Transplantation"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1681\/ASN.2005090955","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation","volume":"17","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","year":"2004","journal-title":"Hypertension"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome proliferator-activated receptor gamma in diabetes and metabolism","volume":"25","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity","volume":"54","year":"2005","journal-title":"Diabetes"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5551\/jat.14.133","article-title":"Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma","volume":"14","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2337\/diacare.27.4.1015","article-title":"Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2337\/diacare.28.3.757","article-title":"Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences","volume":"28","year":"2005","journal-title":"Diabetes Care"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-4-6","article-title":"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome","volume":"4","year":"2005","journal-title":"Cardiovasc Diabetol"},{"key":"bib17-20231002","first-page":"3","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)","volume":"32","year":"2009","journal-title":"Hypertens Res"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF02850002","article-title":"Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes","volume":"24","year":"2007","journal-title":"Adv Ther"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijcard.2012.02.008","article-title":"Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials","volume":"157","year":"2012","journal-title":"Int J Cardiol"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1291\/hypres.31.601","article-title":"Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro","volume":"31","year":"2008","journal-title":"Hypertens Res"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/clp.09.45","article-title":"Depot specificities of PPARg ligand actions on lipid and glucose metabolism and their implication in PPARg-mediated body fat redistribution","volume":"4","year":"2009","journal-title":"Clin Lipidol"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","article-title":"Adiponectin\u2014journey from an adipocyte secretory protein to biomarker of the metabolic syndrome","volume":"257","year":"2005","journal-title":"J Intern Med"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/endo.143.3.8662","article-title":"Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization","volume":"143","year":"2002","journal-title":"Endocrinology"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","year":"2004","journal-title":"Circ Res"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2011.11.070","article-title":"Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials","volume":"156","year":"2012","journal-title":"Int J Cardiol"},{"key":"bib27-20231002","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1600-6143.2007.01928.x","article-title":"Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence","volume":"7","year":"2007","journal-title":"Am J Transplant"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/jpet.103.055616","article-title":"Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity","volume":"307","year":"2003","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201902000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T20:03:06Z","timestamp":1696276986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201902000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000861","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}